Cover Image

Drug survival rate of dupilumab in Japanese patients with atopic dermatitis

Saved in:

Bibliographic Details
Main Authors:	Susumu Ichiyama (Author), Michiko Ito (Author), Toshihiko Hoashi (Author), Naoko Kanda (Author), Hidehisa Saeki (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024)

The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2023)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
by: Teppei Hagino, et al.
Published: (2024)

Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance
by: Hidehisa Saeki, et al.
Published: (2023)

An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis
by: Hidehisa Saeki, et al.
Published: (2024)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023)

Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
by: Francesca Barei, et al.
Published: (2024)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023)

Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis
by: Hidehisa Saeki, et al.
Published: (2024)

Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting
by: Ken Igawa, et al.
Published: (2023)

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
by: Shan J, et al.
Published: (2022)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
by: Sandra Ferreira, et al.
Published: (2020)

Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab
by: Mingxia Wang, et al.
Published: (2022)

Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023)

Alopecia areata after dupilumab for atopic dermatitis
by: Krystal Mitchell, MBA, et al.
Published: (2018)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
by: Amanda E. Zubek, MD, PhD, et al.
Published: (2021)

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
by: Shiyu Zhang, et al.
Published: (2023)

Dupilumab in atopic dermatitis patients with chronic hepatitis B
by: Masako Matsutani, et al.
Published: (2022)

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study
by: Jorge R. Georgakopoulos, MD, et al.
Published: (2021)

Drug-induced interstitial lung disease associated with dupilumab for the treatment of atopic dermatitis
by: Bethany F. Wilken, MSc, et al.
Published: (2024)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
by: Andreas Wollenberg, et al.
Published: (2022)

Dupilumab normalizes correlates of lysosomal function in atopic dermatitis
by: Christina Bürgler, et al.
Published: (2024)

Dupilumab for the treatment of alopecia areata in children with atopic dermatitis
by: Sung Kyung Cho, BA, et al.
Published: (2021)

The application of the biological treatment in atopic dermatitis: focus on dupilumab
by: Yu. S. Smolkin, et al.
Published: (2023)

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis
by: Shinji Mitsuyama, et al.
Published: (2023)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023)

Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis
by: Emilie Fowler, et al.
Published: (2019)

Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
by: Marco Ferrari, et al.
Published: (2023)

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
by: Shoko Miyamoto, et al.
Published: (2022)

Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis
by: Lina U. Ivert, et al.
Published: (2019)

Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis
by: Mikołaj Cichoń, et al.
Published: (2023)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
by: Danielle M. Peterson, MD, et al.
Published: (2021)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024)

Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis
by: Aakaash Varma, BA, et al.
Published: (2020)

A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
by: Wang M, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2022)

Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
by: I. S. Krysanov, et al.
Published: (2020)

443 Dupilumab for Children and Adolescents with Atopic Dermatitis: An Asian Perspective
by: Shi Yun Chia, et al.
Published: (2021)